Literature DB >> 12573439

Tumor suppression by Ink4a-Arf: progress and puzzles.

Scott W Lowe1, Charles J Sherr.   

Abstract

The two products of the Ink4a-Arf locus, p16(Ink4a) and p19(Arf) (p14(ARF) in humans), are potent tumor suppressors that regulate the activities of the retinoblastoma protein and the p53 transcription factor. These proteins form part of a signaling network that is disrupted in most, if not all, cancer cells. The Ink4a-Arf locus responds to stress signals, limiting cell proliferation and modulating oncogene-induced apoptosis. Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573439     DOI: 10.1016/s0959-437x(02)00013-8

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  248 in total

1.  Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Authors:  Gottfried E Konecny; Boris Winterhoff; Teodora Kolarova; Jingwei Qi; Kanthinh Manivong; Judy Dering; Guorong Yang; Meenal Chalukya; He-Jing Wang; Lee Anderson; Kimberly R Kalli; Richard S Finn; Charles Ginther; Siân Jones; Victor E Velculescu; Darren Riehle; William A Cliby; Sophia Randolph; Maria Koehler; Lynn C Hartmann; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

2.  Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.

Authors:  Anna V Molofsky; Ricardo Pardal; Toshihide Iwashita; In-Kyung Park; Michael F Clarke; Sean J Morrison
Journal:  Nature       Date:  2003-10-22       Impact factor: 49.962

Review 3.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

4.  Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.

Authors:  Md Kamrul Hasan; Tomoko Yaguchi; Yasumasu Minoda; Takashi Hirano; Kazunari Taira; Renu Wadhwa; Sunil C Kaul
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node.

Authors:  Ken Ito; Bryan Ronain Smith; Natesh Parashurama; Joon-Kee Yoon; Si Yeol Song; Cornelius Miething; Parag Mallick; Scott Lowe; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2012-10-02       Impact factor: 12.701

Review 7.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

8.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Authors:  Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

9.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

10.  Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Authors:  Charnise Goodings; Rati Tripathi; Susan M Cleveland; Natalina Elliott; Yan Guo; Yu Shyr; Utpal P Davé
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.